- Overview
- Activity Format & Credit
- Register for Webinar
- Bonus Commentary
- Overview
-
More
- Activity Format & Credit
- Register for Webinar
- Bonus Commentary
STATEMENT OF NEED
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening thrombotic microangiopathy with a rapid onset and progression and a mortality rate of 10% to 20% with prompt treatment. Onset of aTTP is characterized by severe thrombocytopenia, microangiopathic hemolytic anemia, and a constellation of associated symptoms including hemorrhage, neurologic and renal manifestations, cardiac abnormalities, and mesenteric ischemia (Joly et al, 2017). Survivors of first aTTP events tend to have relapse events which need to be controlled. Rapid recognition and immediate appropriate treatment are critical for achieving optimized outcomes in aTTP. In this activity chaired by Spero Cataland, MD, Professor of Clinical Internal Medicine and Director of Benign Hematology at The Ohio State University, expert faculty will provide insightful guidance on current treatment standards and will discuss emerging therapies with the potential to improve patient outcomes in aTTP.
TARGET AUDIENCE
Hematology fellows, attending faculty, and other health care professionals involved in the treatment of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
- Evaluate the clinical and laboratory features of aTTP that can inform timely and accurate diagnosis
- Discuss how ADAMTS13 activity can be used to guide the management of aTTP
- Assess the mechanism of action, efficacy, and safety of novel anti-von Willebrand factor nanobodies in aTTP as elucidated by recent clinical trials
- Evaluate novel treatment combinations and sequences with the potential to improve the outcomes of patients with aTTP
REGISTRATION
There is no fee to participate in or claim CME credit for this activity. REGISTER HERE
PROVIDED BY
JOINTLY ACCREDITED PROVIDER
In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS
i3 Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.
Physician Assistants
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.
Nurse Practitioners
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
i3 Health endorses the standards of the ACCME that require everyone in a position to control the content of a CME activity to disclose all financial relationships with ineligible companies that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and ineligible companies:
The i3 Health planners, reviewers, and managers have nothing to disclose.
Spero Cataland, MD, discloses that he has served as a consultant for Sanofi and Takeda.
i3 Health has mitigated all relevant financial relationships.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.
TECHNOLOGY REQUIREMENTS FOR VIRTUAL CME ACTIVITIES
For virtual (asynchronous, archived live, home study; synchronous webinars) CME activities, include access to system requirements:
- The Internet browser(s) supported and minimum versions of each required by the learner to complete the online activity.
- The minimum memory, storage, processor, and Internet speeds require by the learner to complete the online activity.
UNAPPROVED USE DISCLOSURE
i3 Health requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
DISCLAIMER
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.
COMMERCIAL SUPPORT
This activity is supported by an independent educational grant from Sanofi.
Aggregate participant data will be shared with commercial supporters of this activity.
CONTACT INFORMATION
Technical queries or questions regarding activity credit should be directed to i3 Health at support@i3health.com.
FORMAT
Live Webinar
CREDIT
1.0 AMA PRA Category 1 Credit™
ESTIMATED TIME TO COMPLETE
1 hour
DATE AVAILABLE
Wednesday, September 4, 2024 at 12:00 pm ET
Acquired thrombotic thrombocytopenic purpura (aTTP) is a life-threatening thrombotic microangiopathy that requires rapid recognition and immediate, appropriate treatment in order to optimize outcomes.
Join Dr. Spero Cataland on 9/4/24 at 12:00 pm ET and gain expert perspectives on the following:
- Features and presentations of aTTP that can help inform diagnosis
- The role of ADAMTS13 activity and how it can be used to guide management
- The recent approval of caplacizumab and other emerging data on anti–von Willebrand factor therapies
- Ways to minimize relapse risk and optimize supportive care for aTTP survivors
- And much more!
Last year, Dr. Spero Cataland, Professor of Internal Medicine and Benign Hematology Section Head at The Ohio State University, Wexner Medical Center, served as chair of i3 Health’s CME/NCPD activity, Current Standards and New Directions in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura. With new developments in the field occurring since recording the activity, Dr. Cataland sat down to provide an update on the rapidly evolving field of aTTP research.